Belzutifan
PT2977 is a potential treatment for clear cell renal cell carcinoma (ccRCC). PT2977 is an orally active and selective HIF-2α inhibitor (IC50: 9 nM). PT2977, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile.
| Catalog Number | T16679 |
| Alternative Name(s) | PT2977 , MK-6482 |
| Research Area | Angiogenesis|||Chromatin/Epigenetic |
| Molecular Formula | C17H12F3NO4S |
| CAS# | 1672668-24-4 |
| Purity | 99.34% |
| SMILES | CS(c(cc1)c([C@@H]([C@@H]([C@@H]2F)F)O)c2c1Oc1cc(F)cc(C#N)c1)(=O)=O |
| Size | 50 mg |
| Supplier Page | https://www.targetmol.com/compound/Belzutifan |
| Additional Information | https://www.targetmol.com/datasheet/T16679 |